StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)
by Tristan Rich · The Markets DailyStockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research note released on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Trading Up 0.8 %
Shares of GLMD stock opened at $3.85 on Wednesday. The company’s fifty day simple moving average is $4.69 and its 200-day simple moving average is $4.36. Galmed Pharmaceuticals has a 52 week low of $2.73 and a 52 week high of $23.80. The company has a market cap of $2.46 million, a PE ratio of -0.22 and a beta of 0.73.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last issued its earnings results on Wednesday, August 28th. The biopharmaceutical company reported $2.16 earnings per share for the quarter.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Featured Stories
- Five stocks we like better than Galmed Pharmaceuticals
- What Does Downgrade Mean in Investing?
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- How to Use Stock Screeners to Find Stocks
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- High Dividend REITs: Are They an Ideal Way to Diversify?
- 4 Quirky ETFs With Big Potential for Impressive Gains